Work Package 5 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.

Slides:



Advertisements
Similar presentations
EUROCHIP-3 WORK PACKAGES. MAIN WORK PACKAGES of EUROCHIP-3 Ahti Anttila Adherence to cervical screening in 5 Eastern EU countries Renée Otter Population-based.
Advertisements

EUROCHIP-3: WP-4 Publications Paolo Baili Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
High Resolution data for rare cancers Annalisa Trama Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy ) WORKSHOP FOR A EUROPEAN HIGH RESOLUTION.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
Cornelis J.H. van de Velde, MD, PhD,FRCPS(hon)FACS(hon) Professor of Surgery President ECCO - the European Cancer Organization Past-President European.
FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Public Health Programme EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL EUROCHIP-3 WP-4 Update EUROCHIP: EUROpean Cancer Health Indicator.
European Partnership for Action Against Cancer (EPAAC)
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Keith Comiskey, Department of Health.  CANCON – European Guide on Quality Improvement in Comprehensive Cancer Control  Runs from Feb 2014 to Feb 2017.
Renee Otter WP5 leader. Health Strategies in Europe. Lisbon, July Coleman M.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
Name Speaker This work is part of the Joint Action on Improving Quality in HIV Prevention (Quality Action), which has received funding from the European.
Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
Work Package 7 Information for patients with rare cancers WP leader: Francesco De Lorenzo.
1 EUROPA DONNA – The European Breast Cancer Coalition Susan Knox, Executive Director KEEPING BREAST CANCER ON THE EUROPEAN HEALTH AGENDA.
RARECARE project Cancer registries and rare cancers: quality of data, supplementary information RARECARE WP6, 3 rd meeting th National Institute of Public.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
High Resolution Studies within the European Cancer Information System Cooperation with EPAAC Riccardo Capocaccia Istituto Superiore di Sanità (ISS), Italy.
Objectives of Work Package 5 objectives for today Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
Work Package 2 Dissemination of the project RARECARENet Aidan Hutchison on behalf of Professor Ian Kunkler University of Edinburgh.
DISCUSSION. EUROCHIP-2 ACTION PLAN COUNTRY 1COUNTRY 2COUNTRY 3 COUNTRY 30 ACTION1ACTION1 ACTION2ACTION2 ACTION3ACTION3 ACTION3ACTION3 ACTION4ACTION4 ACTION4ACTION4.
Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)
March 2001Management of Thyroid CancerInformation Projects Team THE MANAGEMENT OF PATIENTS WITH THYROID CANCER Cathy Bennett Information Projects Manager.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Information network on rare cancers INFORMATION NETWORK ON RARE CANCERS (RARECARENet) Kick-off meeting - Friday, July Gemma Gatta Fondazione IRCCS,
Work Package 5 Objectives of the work shop Utrecht 17 th January 2014 Information on centres of expertise for rare cancers WP leader: Sabine Siesling.
EUROCHIP-2 EUROCHIP-2 - The Action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Federal Centre for Health Education (BZgA), Germany This work is part of the Joint Action on Improving Quality in HIV Prevention (Quality Action), which.
Clinical Research Networks Notifications Practice Policy Stewardship Lives Saved Diagnostics Pathogenesis Incidence Outcome Risk Factors Treatment Public.
Organization and guideline development April 2010 ACCC The Netherlands.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
May 2001 Management of Thyroid Cancer Information Projects Team THE MANAGEMENT OF PATIENTS WITH THYROID CANCER Cathy Bennett Information Projects Manager.
RARECARE project Data quality and supplementary information Granada, March 25 th 2009 Andalusian School of Public Health.
The Health Roundtable Improving data collection rates, while improving quality Presenter: Sandra Avery Liverpool Innovation Poster Session HRT1215 – Innovation.
Work Package 5 The way forward Utrecht 17 th January 2014 Timeline for the High Resolution study Jan Maarten van der Zwan.
Information network on rare cancers Work Package 4 Information on epidemiology of rare cancers Riccardo Capocaccia and Sandra Mallone Cancer Epidemiology.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Fondazione IRCCS “Istituto Nazionale dei Tumori” Milan Public Health Programme EUROPEAN.
Endometrial Cancer CPGON Audit. Background Formulating standard management pathways Assessing compliance with existing pathways Understanding areas of.
EUNetPaS is a project supported by a grant from the EAHC. The sole responsibility for the content of this presentation lies with the author(s). The EAHC.
PREPARED BY Cancer Programme Work Programme 2012/13.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
 Nearly 20 years old  Achieved College Status 2013  National ‘go to’ group for cancer nursing and cancer care  Influential  Submissions and lobbying.
RARECARE project Proposal for improving data quality on rare cancers with high priority Granada, March 25 th 2009 Andalusian School of Public Health.
Aim: Describe how new health care professionals are deployed
Oesophago–Gastric Cancer
Patient Empowerment in Oncology Birgit BEGER, ECCO CEO
NICE Guidance – Service delivery for patients with Sarcomas
WP 4 – EPIDEMIOLOGY GEMMA Gatta
JARC – Work Package 5 Assuring Quality of Care 12 month Report
Oesophago–Gastric Cancer
Working Package 7 (WP7) Health Care
JARC General Assembly, Oct 16th, 2017
STEERING COMMITTEE MEETING
‘Improving Outcomes for people with skin tumours, including Melanoma’
National Oesophago-Gastric Cancer Audit 2018 Annual Report: Slide set
Regional radiotherapy and oncology network in SEE countries
General Assembly, 26th October, 2018, Milan
WP 10 National Cancer Plans Prepared by:
Josep M. Borras Milano, October 25, 2018
- Kick-off meeting - ERANET Cofund BlueBio WP4 (Leader: AEI)
Presentation transcript:

Work Package 5 Information on centres of expertise for rare cancers WP leader: Sabine Siesling

Information network on rare cancers Work Package 5 Aim – To identify the qualification criteria for centres Centres of Expertise (CoE) for rare cancers Deliverable (No: 7) – Report identifying criteria indicating the level/quality of expertise for rare cancers management

Information network on rare cancers How?

Information network on rare cancers How? with a wide consensus process and high resolution studies and feedback/discussion on the results Together with partners, collaborators, clinicians, patients, scientific societies, health authorities

Information network on rare cancers Partners WP5 Associated partner: INT, ISS, UEDIN, ECPC, NOH, NCR, CSF, OILJ Collaborating partners: RCE (Rare cancers Europe), EPAAC, ESSO, ESO, INSERM (Orphanet), Centre of Leon Bernard, ESMO, LeukaNet, ECCO – To be determined: experts for selected tumour types!

Information network on rare cancers Milestones Consensus meeting on criteria CoE A protocol for the high resolution study Data collection and analysis Meeting to discuss the results Final dissemination meeting with experts held/report

Information network on rare cancers General criteria General criteria for CoE on all rare diseases available – European Union Committee of Experts of rare diseases (EUCERD) – Multidisciplinary scientific society – Patient organizations – Policy makers

Information network on rare cancers Possible general criteria (EUCERD): 1) the attractiveness measured through the volume of cases treated (link to WP4), 2) the capacity to produce and adhere to clinical guidelines (i.e. staging procedure and treatment), 3) outcomes (i.e. surgical free margins, number of revision surgery, survival and recurrence),

Information network on rare cancers Possible general criteria (EUCERD): 4) the availability of multidisciplinary team, 5) the collaboration with other centers of expertise at national and international level (also for clinical trials). 6) capacity to participate in data collection (clinical research and public health in relation to CR)

Information network on rare cancers Specific criteria/indicators criteria for expert groups Develop tumour specific indicators for CoE on specific rare tumours preferably based on guidelines All experts involved in diagnostics and treatment for specific tumour Pathology, medical oncology, surgery, radiotherapy, patient advocacy groups

Information network on rare cancers Specific criteria/indicators Develop tumour specific indicators for CoE on specific rare tumours preferably based on guidelines > discussion on level of detail Based on patient pathway – Diagnosis – Treatment – Follow-up

Information network on rare cancers Define criteria for the indicators Valid Reliable Reveal differences Describe either structure (challenge to collect), process or outcome Influences outcome of the patient (difference in indicator matter) Registration by CR

Information network on rare cancers Specific criteria/indicators examples Diagnosis: – Use of imaging/specific diagnostics – Stage at time of diagnosis – Pathology report (reviewed) – Pre-treatment MDT – Availability of relevant disciplines at MDT (pathologist etc) – time between pathological confirmation and first treatment

Information network on rare cancers Specific criteria/indicators examples Treatment: – Referral pattern = hospital of diagnosis and hospital of treatment – According to guideline – Free margins after surgery/number of revisions – Post-treatment MDT – Availability of different disciplines at MDT (pathologist etc) – time between first treatment and adjuvant therapy

Information network on rare cancers Specific criteria/indicators examples Follow-up: – 1, 3, 5 year survival (WP4) – Recurrence within 5 years after diagnosis – Patient satisfaction (not collected by CR!) – Information to patient about treatment General: – Organisation of care: a case manager for every patient (too much detail, survey? Not by data from CR)

Information network on rare cancers Specific criteria/indicators plan of action Check availablility in EU Cancer Registries (CR) Some CR will be invited to collect information from clinical files in retrospect (time period important for ability to find data (electronically), partly overlap of period of Wp4) Develop a protocol to retrieve data for these High Resolution Studies

Information network on rare cancers High Resolution Studies Collect data on specific indicators by high resolution study using a set protocol Selected number of CR (partners NL, Finland, Italy, Ireland, Bulgaria, Slovenia i.e. based on EUROCHIP survey on availablity stage etc) Analyse data Discuss results with experts Describe an advice upon CoE for the specific rare cancers

Information network on rare cancers Criteria for Selection of rare cancer types Which rare cancers to select for High Resolution Study? Rationale: - Expected difference in clinical management (adherence to guidelines) - Expected difference in clinical outcome - Take geographical patterns and trends in incidence into account (mesothelioma, Thyroid cancer): WP4! - Already work done by other groups (could be included in expert groups)

Information network on rare cancers Proposal for High Resolution Studies Five (?) groups of rare tumours we could focus on; 1. Mesothelioma (Italy, NL, clusters) 2. Sarcomas (EPAAC) 3. Leukemia (partner) 4. Endocrine tumours (thyroid cluster?, Finland) 5. Neuroendocrine tumours

Information network on rare cancers Timeline M2: Kick off meeting (Now) M3: Start preparing consensus meeting with experts M7: Start developing protocol M8: Consensus meeting with experts M9: Send out protocol for data on indicators M9-M17: Collect data from CR M17-M19: Data analyses M21: Data collection and data analyses completed M23: Meeting to discuss output with CR M24: Meeting present results to experts

Information network on rare cancers Expected results and output Final Deliverable (No.7): Report identifying criteria indicating the level/quality of expertise for rare cancers management  This report will lead to recommendation that can be used for selecting centres of expertise throughout Europe

Information network on rare cancers Link to other WP’s

Information network on rare cancers Questions and suggestions

Information network on rare cancers

Introduction IKNL and – The Netherlands Cancer Registry European projects  The RARECARE project  EUROCHIP  EPAAC RARECARENet Partner Work Package 5 leader

Information network on rare cancers Content: ADAPT!!! Aim of Work Package 5 Milestones Methodology Timeline Example Expected results and output Link to other Work Packages

Information network on rare cancers Strategy: Example Identify the common indicators on rare disease (example: EUCERD indicators) – Identify existing indicators and criteria on specific tumour – Discuss criteria with experts and find consensus Develop protocol on data collection Collect data and analyse for the criteria data for the experts